

Supplementary Table 1. Univariate analysis of clinical, treatment, and outcome factors associated with overall survival.

Parameter	Hazard ratio	95% confidence interval	p-value
Age (continuous)	1.01	0.99-1.04	0.328
Gender (female vs. male)	1.25	0.67-2.33	0.491
Pre-SABR ECOG performance status (continuous)	1.40	1.03-1.90	0.033
Pack-years smoking (continuous)	1.00	0.99-1.01	0.914
Smoking at last follow-up (yes vs. no)	1.07	0.38-3.02	0.903
Receipt of chemotherapy (yes vs. no)	0.45	0.24-0.87	0.018
Cycles of chemotherapy			
< 4 cycles vs. none	0.36	0.13-1.02	0.055
≥ 4 cycles vs. none	0.47	0.24-0.94	0.032
Unknown vs. none	0.58	0.13-2.53	0.465
Timing of chemotherapy			
Pre-SABR vs. none	0.70	0.29-1.65	0.41
Post-SABR vs. none	0.37	0.18-0.77	0.007
Pre-SABR/concurrently vs. none	0.14	0.02-1.25	0.078
Tumor location (central vs. peripheral)	0.71	0.32-1.53	0.378
Mediastinal nodal sampling (yes vs. no)	0.80	0.39-1.63	0.533
Tumor size			
Continuous	1.20	0.97-1.49	0.086
> 2 cm vs. ≤ 2 cm	1.81	0.93-3.54	0.08
> 3 cm vs. ≤ 3 cm	1.10	0.57-2.15	0.77
PCI (yes vs. no)	0.49	0.22-1.08	0.076
Radiation dose			
Continuous	0.97	0.90-1.04	0.401
≥ 50 Gy vs. < 50 Gy	0.60	0.21-1.74	0.35
Biologically effective dose			
Continuous	1.00	0.99-1.01	0.859
> 130 Gy vs. < 130 Gy	1.14	0.58-2.21	0.707
Tumor response			
PR vs. CR	1.60	0.73-3.53	0.242
SD/PD vs. CR	1.20	0.47-3.06	0.698
Nodal failure (yes vs. no)	0.06	0.02-0.16	<0.001
Elsewhere lung failure (yes vs. no)	0.92	0.38-2.23	0.86
Distant metastasis			
Yes vs. no	0.79	0.35-1.79	0.577
Time to distant metastasis	0.997	0.995-0.998	<0.001
Any failure			
Yes vs. no	1.06	0.48-2.32	0.887
Time to any failure	0.997	0.996-0.999	<0.001

Bold p-values are statistically significant. ECOG, Eastern Cooperative Oncology Group; SABR, stereotactic body radiation therapy; PCI, prophylactic cranial irradiation; Gy, Gray; PR, partial response; CR, complete response; SD, stable disease; PD, progressive disease

Supplementary Table 2. Univariate analysis of clinical, treatment, and outcome factors associated with disease-free survival.

Parameter	Hazard ratio	95% confidence interval	p-value
Age (continuous)	1.01	0.97-1.05	0.657
Gender (female vs. male)	0.90	0.43-1.89	0.782
Pre-SABR ECOG performance status (continuous)	1.36	0.93-1.98	0.11
Pack-years smoking (continuous)	1.00	0.99-1.01	0.844
Smoking at last follow-up (yes vs. no)	0.62	0.15-2.62	0.519
Receipt of chemotherapy (yes vs. no)	0.42	0.20-0.90	0.026
Cycles of chemotherapy			
< 4 cycles vs. none	0.36	0.11-1.18	0.093
≥ 4 cycles vs. none	0.44	0.20-1.00	0.05
Unknown vs. none	0.43	0.06-3.30	0.415
Timing of chemotherapy			
Pre-SABR vs. none	0.67	0.24-1.90	0.454
Post-SABR vs. none	0.35	0.15-0.82	0.016
Pre-SABR/concurrently vs. none	0.15	0.01-1.66	0.123
Tumor location (central vs. peripheral)	0.71	0.27-1.88	0.494
Mediastinal nodal sampling (yes vs. no)	0.57	0.22-1.50	0.253
Tumor size			
Continuous	1.10	0.85-1.42	0.459
> 2 cm vs. ≤ 2 cm	1.00	0.48-2.08	0.992
> 3 cm vs. ≤ 3 cm	0.78	0.33-1.83	0.565
PCI (yes vs. no)	0.42	0.14-1.22	0.111
Radiation dose			
Continuous	0.97	0.90-1.05	0.468
≥ 50 Gy vs. < 50 Gy	0.38	0.15-0.95	0.039
Biologically effective dose			
Continuous	0.99	0.98-1.01	0.349
> 130 Gy vs. < 130 Gy	0.77	0.33-1.81	0.551
Tumor response			
PR vs. CR	3.37	1.12-10.10	0.03
SD/PD vs. CR	2.45	0.73-8.25	0.148

Bold p-values are statistically significant. ECOG, Eastern Cooperative Oncology Group; SABR, stereotactic body radiation therapy; PCI, prophylactic cranial irradiation; Gy, Gray; PR, partial response; CR, complete response; SD, stable disease; PD, progressive disease

Supplementary Table 3. Univariate analysis of clinical, treatment, and outcome factors associated with disease-specific survival.

Parameter	Hazard ratio	95% confidence interval	p-value
Age (continuous)	1.02	0.98-1.07	0.325
Gender (female vs. male)	0.65	0.23-1.84	0.422
Pre-SABR ECOG performance status (continuous)	1.22	0.73-2.03	0.445
Pack-years smoking (continuous)	0.998	0.98-1.02	0.809
Smoking at last follow-up (yes vs. no)	0.71	0.09-5.48	0.744
Receipt of chemotherapy (yes vs. no)	0.51	0.18-1.44	0.201
Cycles of chemotherapy < 4 cycles vs. none	0.50	0.10-2.53	0.402
≥ 4 cycles vs. none	0.56	0.19-1.68	0.304
Timing of chemotherapy Pre-SABR vs. none	0.78	0.19-3.16	0.732
Post-SABR vs. none	0.37	0.11-1.21	0.101
Tumor location (central vs. peripheral)	1.001	0.32-3.11	0.999
Mediastinal nodal sampling (yes vs. no)	0.34	0.08-1.50	0.154
Tumor size Continuous	1.23	0.89-1.71	0.218
> 2 cm vs. ≤ 2 cm	0.95	0.34-2.62	0.92
> 3 cm vs. ≤ 3 cm	1.13	0.39-3.31	0.824
PCI (yes vs. no)	0.48	0.14-1.72	0.261
Radiation dose Continuous	0.96	0.86-1.08	0.501
≥ 50 Gy vs. < 50 Gy	0.97	0.12-7.58	0.977
Biologically effective dose Continuous	0.99	0.97-1.01	0.204
> 130 Gy vs. < 130 Gy	0.75	0.24-2.38	0.63
Tumor response PR vs. CR	1.67	0.43-6.47	0.457
SD/PD vs. CR	2.55	0.63-10.29	0.187
Nodal failure Yes vs. no	0.16	0.02-1.08	0.061
Time to nodal failure	0.988	0.981-0.995	0.001
Elsewhere lung failure (yes vs. no)	1.56	0.43-5.61	0.499
Distant metastasis Yes vs. no	2.86	0.62-13.24	0.179
Time to distant metastasis	0.994	0.989-0.999	0.016
Any failure (time to any failure)	0.996	0.992-1.001	0.114

Bold p-values are statistically significant. ECOG, Eastern Cooperative Oncology Group; SABR, stereotactic body radiation therapy; PCI, prophylactic cranial irradiation; Gy, Gray; PR, partial response; CR, complete response; SD, stable disease; PD, progressive disease

Supplementary Table 4. Univariate analysis of clinical, treatment, and outcome factors associated with distant metastasis-free survival.

Parameter	Hazard ratio	95% confidence interval	p-value
Age (continuous)	1.01	0.97-1.05	0.615
Gender (female vs. male)	0.74	0.31-1.73	0.483
Pre-SABR ECOG performance status (continuous)	1.17	0.76-1.81	0.471
Pack-years smoking (continuous)	1.00	0.98-1.01	0.726
Smoking at last follow-up (yes vs. no)	0.35	0.05-2.57	0.299
Receipt of chemotherapy (yes vs. no)	0.54	0.22-1.29	0.164
Cycles of chemotherapy < 4 cycles vs. none	0.86	0.26-2.80	0.798
≥ 4 cycles vs. none	0.50	0.19-1.31	0.158
Timing of chemotherapy Post-SABR vs. none	0.59	0.18-1.98	0.388
Tumor location (central vs. peripheral)	0.76	0.26-2.25	0.618
Mediastinal nodal sampling (yes vs. no)	0.24	0.06-1.05	0.058
Tumor size Continuous	1.20	0.90-1.60	0.212
> 2 cm vs. ≤ 2 cm	1.20	0.51-2.81	0.673
> 3 cm vs. ≤ 3 cm	0.97	0.38-2.50	0.95
PCI (yes vs. no)	0.42	0.12-1.46	0.173
Radiation dose Continuous	0.96	0.88-1.05	0.325
≥ 50 Gy vs. < 50 Gy	0.30	0.11-0.83	0.02
Biologically effective dose Continuous	0.99	0.97-1.01	0.206
> 130 Gy vs. < 130 Gy	0.67	0.25-1.82	0.434
Tumor response PR vs. CR	2.28	0.73-7.08	0.154
SD/PD vs. CR	1.39	0.37-5.23	0.623
Local failure Yes vs. no	0.28	0.02-4.61	0.375
Time to local failure	0.98	0.96-0.99	0.005
Nodal failure Yes vs. no	0.39	0.10-1.55	0.182
Time to nodal failure	0.99	0.98-1.00	0.003
Elsewhere lung failure Yes vs. no	1.26	0.44-3.67	0.666
Time to elsewhere lung failure	0.98	0.96-0.99	0.005

Bold p-values are statistically significant. ECOG, Eastern Cooperative Oncology Group; SABR, stereotactic body radiation therapy; PCI, prophylactic cranial irradiation; Gy, Gray; PR, partial response; CR, complete response; SD, stable disease; PD, progressive disease

Supplementary Table 5. Univariate analysis of clinical, treatment, and outcome factors associated with local control.

Parameter	Hazard ratio	95% confidence interval	p-value
Age (continuous)	0.999	0.88-1.13	0.987
Pre-SABR ECOG performance status (continuous)	0.25	0.03-2.16	0.207
Pack-years smoking (continuous)	1.02	0.99-1.05	0.256
Receipt of chemotherapy (yes vs. no)	0.46	0.03-7.39	0.584
Cycles of chemotherapy			
< 4 cycles vs. none	0.98	0.05-19.99	0.991
≥ 4 cycles vs. none	0.32	0.01-6.94	0.467
Tumor location (central vs. peripheral)	8.76	0.79-96.85	0.077
Tumor size			
Continuous	1.10	0.48-2.52	0.826
> 2 cm vs. ≤ 2 cm	0.67	0.05-8.51	0.761
PCI (yes vs. no)	1.28	0.12-14.27	0.84
Radiation dose			
Continuous	0.71	0.53-0.95	0.021
≥ 50 Gy vs. < 50 Gy	0.11	0.01-1.82	0.124
Biologically effective dose (continuous)	0.95	0.87-1.03	0.193
Nodal failure			
Yes vs. no	1.65	0.08-33.79	0.746
Time to any failure	0.99	0.96-1.01	0.35
Elsewhere lung failure			
Yes vs. no	75.73	0.18-32298.36	0.161
Time to any failure	0.99	0.97-1.00	0.088
Distant metastasis (yes vs. no)	0.25	0.02-3.13	0.281

Bold p-values are statistically significant. ECOG, Eastern Cooperative Oncology Group; SABR, stereotactic body radiation therapy; PCI, prophylactic cranial irradiation; Gy, Gray; PR, partial response; CR, complete response; SD, stable disease; PD, progressive disease